Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3...( SEATTLE June 22 /- Updated fo...),Health

SEATTLE, June 22 /PRNewswire-FirstCall/ --

Updated follow-up phase III EXTEND (PIX 301) clinical trial data enhances previously reported superior response rates for pixantrone over comparator including in high risk patient subgroups

Additional Clinical Studies Also Highlighted at Pan Pacific Conference

• Randomized phase III; PIX 302-Pixantrone plus rituximab significantly improves CR rate (35% vs. 11%), ORR (75% vs. 33%) and time to progression (TTP) (13.2 vs. 8.1 months) compared to rituximab alone in relapsed indolent NHL
• Phase II; AZA I06- Pixantrone plus fludarabine, and rituximab (FPD-R regimen) produces high CR/CRu (70%) and ORR (89%) in multiple relapsed indolent NHL

Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that an overview of CTI's pixantrone clinical studies in aggressive and indolent NHL including follow-up data and subgroup analyses of high risk patients from the phase III EXTEND PIX 301 clinical trial of pixantrone (the "PIX 301 EXTEND trial") is being presented at the Pan Pacific Lymphoma conference by Dr. Richard Van der Jagt of the Ottawa General Hospital.

Pixantrone PIX 301 EXTEND Trial Follow-up Data and Subgroup Analyses

Initial follow-up data in the PIX 301 EXTEND trial demonstrated that three additional patients in the pixantrone arm achieved a CR and one additional patient achieved a CRu during the follow-up period of patients that received chemotherapy on the control arm. Including the treatment and follow-up period, pixantrone had a significantly higher complete remission rate compared to the patients who received standard chemotherapy (CR/CRu rate=24% (17 of 70 patients) for pixantrone vs. CR/CRu rate=7% (5 of 70 patients) for standard chemotherapy; p=0.009). No patient in the standard chemotherapy
'/>"/>